You are not alone.
We work with founders who obsess over the problem they are solving. We also like unfair advantages – this can be your contacts and your unique understanding of a problem or your technical ability and insight. If you are worried about your runway to Series A funding, get in touch.
We have the capital, time, and expertise you need to get there.
Access a hassle-free convertible loan note
Fast, easy, and between £250k-£1.5m. Designed to give entrepreneurs a longer runaway to achieve Series A metrics and milestones now the bar is so much higher.
Prepare for Series A and follow-on funding
We provide you with operational support, go-to-market advice, test your financial models, scrutinise your business plans and fine-tune all relevant pitch assets to prepare you for future funding.
Support beyond the next round of fundraising
Our suite of supporting operational, commercial and strategic services includes sales, customer success, org design, legal, tax, co-sec, risk management and board composition.
We’ve been through it, on both sides of the fence.
We are entrepreneurs
Ex-founders of UK businesses that have raised over £100m, achieved combined value of over £2B and successfully launched into the US and global markets.
We are investment veterans
We’ve set up, operated and governed global institutional funds and platforms that have managed and administered over £100bn in capital.
Growth consultation, post-investment
We care about aligning shareholder interests to the founders vision and appreciate that companies and investors want to focus on sustainable growth.
Our post-investment consulting services are an integral part of our partnering entrepreneur’s management team, closing the communication gap that is often lost with service providers.
What we look for
Although we are sector agnostic, we favour companies that operate in our areas of expertise. This includes B2B and B2B2C business models operating in professional services, retail and manufacturing sectors. We like some deep tech expertise but we’re unlikely to consider life science companies.